[go: up one dir, main page]

RU2008140653A - Производные прегабалина для лечения фибромиалгии и других расстройств - Google Patents

Производные прегабалина для лечения фибромиалгии и других расстройств Download PDF

Info

Publication number
RU2008140653A
RU2008140653A RU2008140653/15A RU2008140653A RU2008140653A RU 2008140653 A RU2008140653 A RU 2008140653A RU 2008140653/15 A RU2008140653/15 A RU 2008140653/15A RU 2008140653 A RU2008140653 A RU 2008140653A RU 2008140653 A RU2008140653 A RU 2008140653A
Authority
RU
Russia
Prior art keywords
pain
use according
disease
fibromyalgia
treatment
Prior art date
Application number
RU2008140653/15A
Other languages
English (en)
Inventor
Дэвид Джеймс ДУЛИ (US)
Дэвид Джеймс ДУЛИ
Чарльз Прайс Мл. ТЭЙЛОР (US)
Чарльз Прайс Мл. ТЭЙЛОР
Эндрю Джон ТОРП (US)
Эндрю Джон Торп
Дэвид Юрген ВУСТРОУ (US)
Дэвид Юрген Вустроу
Original Assignee
Уорнер-Ламберт Компани Ллс (Us)
Уорнер-Ламберт Компани Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32600153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2008140653(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Уорнер-Ламберт Компани Ллс (Us), Уорнер-Ламберт Компани Ллс filed Critical Уорнер-Ламберт Компани Ллс (Us)
Publication of RU2008140653A publication Critical patent/RU2008140653A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1. Применение (3S,5R)-3-аминометил-5-метилоктановой кислоты или ее фармацевтически приемлемой соли для получения лекарственного средства для лечения у млекопитающего заболевания, выбранного из фибромиалгии, боли в животе или боли гинекологического происхождения и боли, вызванной усиленными сокращениями мочевого пузыря. ! 2. Применение по п.1, где млекопитающим является человек. ! 3. Применение по любому из п.1 или 2, где заболевание представляет собой фибромиалгию. ! 4. Применение по любому из пп.1 или 2, где заболевание представляет собой боль, вызванную усиленными сокращениями мочевого пузыря. ! 5. Применение по любому из п.1 или 2, где заболевание представляет собой боль в животе или боль гинекологического происхождения. ! 6. Применение по п.5, где боль представляет собой дисменорею. ! 7. Применение по п.5, где боль представляет собой боль при родах. ! 8. Применение по п.5, где боль представляет собой боль, связанную с эндометриозом.

Claims (8)

1. Применение (3S,5R)-3-аминометил-5-метилоктановой кислоты или ее фармацевтически приемлемой соли для получения лекарственного средства для лечения у млекопитающего заболевания, выбранного из фибромиалгии, боли в животе или боли гинекологического происхождения и боли, вызванной усиленными сокращениями мочевого пузыря.
2. Применение по п.1, где млекопитающим является человек.
3. Применение по любому из п.1 или 2, где заболевание представляет собой фибромиалгию.
4. Применение по любому из пп.1 или 2, где заболевание представляет собой боль, вызванную усиленными сокращениями мочевого пузыря.
5. Применение по любому из п.1 или 2, где заболевание представляет собой боль в животе или боль гинекологического происхождения.
6. Применение по п.5, где боль представляет собой дисменорею.
7. Применение по п.5, где боль представляет собой боль при родах.
8. Применение по п.5, где боль представляет собой боль, связанную с эндометриозом.
RU2008140653/15A 2002-12-13 2008-10-13 Производные прегабалина для лечения фибромиалгии и других расстройств RU2008140653A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43349102P 2002-12-13 2002-12-13
US60/433,491 2002-12-13
US48774003P 2003-07-16 2003-07-16
US60/487,740 2003-07-16

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2005118081/14A Division RU2353358C2 (ru) 2002-12-13 2003-12-03 Производные прегабалина для лечения приливов

Publications (1)

Publication Number Publication Date
RU2008140653A true RU2008140653A (ru) 2010-04-20

Family

ID=32600153

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2005118081/14A RU2353358C2 (ru) 2002-12-13 2003-12-03 Производные прегабалина для лечения приливов
RU2008140653/15A RU2008140653A (ru) 2002-12-13 2008-10-13 Производные прегабалина для лечения фибромиалгии и других расстройств

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2005118081/14A RU2353358C2 (ru) 2002-12-13 2003-12-03 Производные прегабалина для лечения приливов

Country Status (15)

Country Link
US (1) US20090203782A1 (ru)
EP (2) EP1572188A1 (ru)
JP (1) JP2006513257A (ru)
KR (1) KR20050085636A (ru)
CN (1) CN101862317A (ru)
AU (1) AU2003303040B2 (ru)
BR (1) BR0317253A (ru)
CA (1) CA2505788A1 (ru)
MX (1) MXPA05006320A (ru)
NO (1) NO20052264L (ru)
NZ (1) NZ540591A (ru)
PL (1) PL377520A1 (ru)
RU (2) RU2353358C2 (ru)
TW (1) TW200423925A (ru)
WO (1) WO2004054566A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05010515A (es) * 2003-03-31 2006-03-10 Xenoport Inc Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba.
AU2004271796A1 (en) * 2003-09-12 2005-03-24 Warner-Lambert Company Llc Combination comprising an alpha-2-delta ligand and an SSRI and/or SNRI for treatment of depression and anxiety disorders
US20070141684A1 (en) 2005-12-21 2007-06-21 Pfizer Inc Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
CN106163509B (zh) 2014-02-03 2019-05-03 夸德里加生物科学公司 作为化疗剂的β-取代的β-氨基酸及类似物
BR112016017993A2 (pt) 2014-02-03 2017-08-08 Quadriga Biosciences Inc Gama-aminoácidos beta-substituídos e análogos como agentes quimioterapêuticos
WO2017024009A1 (en) 2015-08-03 2017-02-09 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof
CN115739134B (zh) * 2022-11-24 2024-08-02 贵州大学 一种利用三氯化钌废弃物制备氯乙烯合成用复合催化剂的方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
HU222339B1 (hu) * 1992-05-20 2003-06-28 Northwestern University S-(+)-4-amino-3-(2-metil-propil)-butánsav, és gyógyászati szempontból elfogadható sói, ezeket tartalmazó gyógyászati készítmények, valamint az (S)-(+)-4-amino-3-(2-metil-propil)-butánsav előállítása
ATE177101T1 (de) 1992-12-17 1999-03-15 Pfizer Pyrrolopyrimidine als crf antagonisten
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
EP0674624B1 (en) 1992-12-17 1999-01-20 Pfizer Inc. Pyrazoles having crf antagonist activity
CA2150703C (en) 1992-12-17 2002-01-08 Pfizer Limited Substituted pyrazoles
US5670539A (en) * 1993-07-21 1997-09-23 New York State Office Of Mental Health Treatment of movement disorders using large neutral amino acids
US6372792B1 (en) * 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
AU714980B2 (en) * 1996-07-24 2000-01-13 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
CA2263663C (en) 1996-10-23 2006-05-30 Justin Stephen Bryans Substituted gamma aminobutyric acids as pharmaceutical agents
US6127418A (en) * 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
HUP0004310A3 (en) 1997-10-27 2001-11-28 Warner Lambert Co Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents
EP1094803A2 (en) 1998-07-09 2001-05-02 Warner-Lambert Company Use of gaba-analogues for treating insomia
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AU4334900A (en) * 1999-04-09 2000-11-14 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
US6642398B2 (en) * 1999-06-10 2003-11-04 Warner-Lambert Company Mono-and disubstituted 3-propyl gamma-aminobutyric acids
IL146969A0 (en) 1999-06-10 2002-08-14 Warner Lambert Co Mono- and disubstituted 3-propyl gamma-aminobutyric acids
US7164034B2 (en) * 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
ES2287021T3 (es) * 1999-07-22 2007-12-16 University Of Rochester Metodo para el tratamiento de sintomas de variacines hormonales que incluyen el fogaje.
US6281207B1 (en) * 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
HN2000000224A (es) 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
GB2362646A (en) 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
GB2365425A (en) * 2000-08-01 2002-02-20 Parke Davis & Co Ltd Alkyl amino acid derivatives useful as pharmaceutical agents
US20020099013A1 (en) * 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
IL145584A0 (en) * 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
US20020165246A1 (en) * 2001-03-05 2002-11-07 Andrew Holman Administration of sleep restorative agents
AU2002258026B2 (en) * 2001-05-25 2007-08-02 Warner-Lambert Company Llc Liquid pharmaceutical composition

Also Published As

Publication number Publication date
CN101862317A (zh) 2010-10-20
AU2003303040B2 (en) 2009-04-23
WO2004054566A1 (en) 2004-07-01
TW200423925A (en) 2004-11-16
RU2005118081A (ru) 2006-01-20
RU2353358C2 (ru) 2009-04-27
NO20052264D0 (no) 2005-05-10
EP1572188A1 (en) 2005-09-14
BR0317253A (pt) 2005-11-01
US20090203782A1 (en) 2009-08-13
PL377520A1 (pl) 2006-02-06
EP2172197A1 (en) 2010-04-07
AU2003303040A1 (en) 2004-07-09
NZ540591A (en) 2008-03-28
MXPA05006320A (es) 2005-08-26
KR20050085636A (ko) 2005-08-29
JP2006513257A (ja) 2006-04-20
CA2505788A1 (en) 2004-07-01
NO20052264L (no) 2005-09-12

Similar Documents

Publication Publication Date Title
RU2008140653A (ru) Производные прегабалина для лечения фибромиалгии и других расстройств
EP1443928A4 (en) TREATMENT OF NEURODEGENERATIVE DISEASES AND CANCER IN THE BRAIN
EA200400881A1 (ru) Азаарилпиперазины
LU92520I2 (fr) Bédaquiline, ou son sel d'addition d'acide ou de base pharmaceutiquement acceptable, y compris le fumarate de bédaquiline
EA201100506A1 (ru) Комбинация ингибитора протеазы ns3 hcv с интерфероном и рибавирином
GB2414183A (en) Methods and devices for therapeutic treatment cardiac and other pathologies
RU2004138807A (ru) Новые сложные эфиры этоногестрела
RU2008127882A (ru) Лечение пищевода барретта
RU2003103881A (ru) Стоматологический гель для лечения воспалительных заболеваний полости рта
RU2003119858A (ru) Комбинированный хирургический способ лечения ректоцеле
RU2004116737A (ru) Способ дифференциальной оценки состояния плода
SU1748833A1 (ru) Способ лечени звенной болезни желудка и двенадцатиперстной кишки
CN209751250U (zh) 一种新型橡皮链
RU2001120730A (ru) Способ позадилонной кольпосуспензии при стрессовом недержании мочи женщин
RU2004102626A (ru) Способ хирургического лечения осложненных язв желудка
RU53135U1 (ru) Компрессионное устройство для формирования межкишечного анастомоза
RU2003109909A (ru) Средство для лечения заболеваний глаз с метронидазолом и оксиметилурацилом
RU2004130782A (ru) Способ анестезии при оперативных вмешательствах на органах брюшной полости
DK1818052T3 (da) Anvendelse af formoterol i den profylaktiske og/eller terapeutiske behandling af muskelsvind og/eller kakektisk syndrom i forbindelse med kataboliske forhold af visse sygdomme såsom cancer, aids, infektioner, diabetes og andre
RU2000112589A (ru) Способ лапароскопической аппаратной гистерэктомии
RU2009134587A (ru) Способ формирования колостомы
RU2002126534A (ru) Способ непрямого доступа в полость двенадцатиперстной кишки
RU2002119600A (ru) Способ лечения воспалительных заболеваний женских половых органов
PL1514545T3 (pl) Zastosowanie tolperyzonu do leczenia skurczów narządów zbudowanych zasadniczo z mięśni gładkich
Harder et al. The parasacral approach for rectal prolapse